Methods and compositions for live attenuated viruses

Abstract

Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.

What is claimed is: 
     
         1 - 32 . (canceled) 
     
     
         33 . A live attenuated virus composition comprising:
 one or more live, attenuated viruses;   one or more poly(ethylene oxide) and polypropylene oxide) (EO-PO) block copolymers, the one or more EO-PO block copolymers include one or more of poloxamer 338 (Pluronic P108®), poloxamer 335 (Pluronic P105®) and poloxamer 238 (Pluronic F88®),   one or more proteins agents, the one or more protein agents are one or more albumins selected from the group consisting of lactalbumins and serum albumins, and   one or more carbohydrate agents, the one or more carbohydrate agents include trehalose, wherein the composition is capable of reducing the inactivation of the live attenuated virus.   
     
     
         34 . The virus composition of  claim 33 , wherein the live, attenuated viruses are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus families and combinations thereof. 
     
     
         35 . The virus composition of  claim 33 , wherein the live, attenuated viruses are Flaviviruses. 
     
     
         36 . The virus composition of  claim 33 , wherein the composition is in aqueous form. 
     
     
         37 . The virus composition of  claim 33 , wherein the composition is partially or wholly dehydrated. 
     
     
         38 . The virus composition of  claim 33 , wherein the one or more albumins include serum albumins from a vertebrate species. 
     
     
         39 . The virus composition of  claim 33 , wherein the one or more EO-PO block copolymer is poloxamer 338, and at least one protein agent is serum albumin. 
     
     
         40 . The virus composition of  claim 33 , wherein the EO-PO block copolymer concentration is from 0.1 to 4% (w/v). 
     
     
         41 . A method for decreasing inactivation of a live, attenuated virus composition comprising, combining one or more live attenuated viruses with a composition comprising one or more EO-PO block copolymers, the one or more EO-PO block copolymers include one or more of poloxamer 338 (Pluronic P108®), poloxamer 335 (Pluronic P105®) and poloxamer 238 (Pluronic F88®),
 one or more proteins agents, the one or more protein agents are one or more albumins selected from the group consisting of lactalbumins and serum albumins, and 
 one or more carbohydrate agents, the one or more carbohydrate agents include trehalose, wherein the composition is capable of reducing the inactivation of the live attenuated virus. 
 
     
     
         42 . The method of  claim 41 , wherein the live, attenuated viruses are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus families and combinations thereof. 
     
     
         43 . The method of  claim 41 , further comprising partially or wholly dehydrating the combination. 
     
     
         44 . The method of  claim 43 , further comprising partially or wholly re-hydrating the composition prior to administration. 
     
     
         45 . The method of  claim 41 , wherein the composition increases the shelf life of an aqueous virus composition. 
     
     
         46 . The method of  claim 41 , wherein the composition decreases inactivation of an aqueous live, attenuated virus for 24 hours or greater. 
     
     
         47 . The method of  claim 41 , wherein the composition decreases inactivation of an aqueous live, attenuated virus during one or more freeze and thaw cycles. 
     
     
         48 . The method of  claim 41 , wherein the one or more EO-PO block copolymer is poloxamer 338, and the one or more protein agents is serum albumin. 
     
     
         49 . The method of  claim 41 , wherein the virus composition is administered to a subject to reduce the onset of or prevent a health condition. 
     
     
         50 . The method of  claim 49 , wherein the virus is selected from the group consisting of West Nile, Dengue, Japanese encephalitis, St. Louis encephalitis, Tick-borne encephalitis, and Yellow fever. 
     
     
         51 . A kit for decreasing the inactivation of a live, attenuated virus composition comprising:
 at least one container; and   a composition comprising one or more EO-PO block copolymers, the one or more EO-PO block copolymers include one or more of poloxamer 338 (Pluronic P108®), poloxamer 335 (Pluronic P105®) and poloxamer 238 (Pluronic F88®), one or more albumins, the one or more albumins selected from the group consisting of lactalbumins and serum albumins, one or more carbohydrate agents, the one or more carbohydrate agents include trehalose.   
     
     
         52 . The kit of  claim 51 , wherein at least one albumin is serum albumin. 
     
     
         53 . The kit of  claim 51 , wherein the EO-PO block copolymer concentration is from 0.1 to 4% (w/v). 
     
     
         54 . The kit of  claim 52 , wherein the serum albumin concentration is from 0.001 to 3% (w/v). 
     
     
         55 . The kit of  claim 51 , wherein the composition further comprises one or more live, attenuated viruses. 
     
     
         56 . The kit of  claim 51 , wherein the live, attenuated viruses are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus families and combinations thereof.